Remove keyword fda-approvals
article thumbnail

Overview of FDA Expedited Development and Approval Programs for Serious Conditions

Impact Pharmaceutical Services

In May of 2014 and February of 2019 , the FDA released final Guidance for Industry outlining the Agency’s policies and procedures regarding expedited development and review programs for new drugs and biologics intended to treat serious or life-threatening conditions. Overview of FDA’s Expedited Approval Programs.

FDA 52
article thumbnail

Prominent Reasons Behind The Failure Of NAMPT inhibitors And Key Strategies Adopted By Developers To Overcome Such Challenges

Roots Analysis

As a starting point, the information on terminated, suspended and withdrawn trials was collated from clinicaltrials.gov and PubMed using relevant search keywords. This lack of drug efficacy has been a significant factor in drug failure, as it has prevented NAMPT inhibitors from receiving regulatory approval.

FDA 40